Neurocognitive Trajectories After BCMA CAR-T
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWake Forest University Health Sciences
About this trial
The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).
Eligibility criteria
Qualifiers
Ability to understand and willingness to sign an IRB-approved informed consent
Ability to retain independent decision-making capacity as per the enrolling investigator
Age ≥ 18 years of age at the time of consent
Scheduled to receive BCMA CAR-T therapy for RRMM as confirmed by the treating clinician
Disqualifiers
Active central nervous system (CNS) disease
Known neurodegenerative disease or major neurocognitive disorder
Stroke and/or traumatic brain injury (TBI) within 12 months
Concurrent investigational neuroactive drugs
Trial design
Treatments tested in this trial
- Standardized neurocognitive testing
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Wake Forest University Health Sciences
Lead sponsor
Atrium Health Wake Forest Baptist
Collaborator
Source ClinicalTrials.gov